Encouraging Signals For New Cancer Cell Therapy Strategies

AACR highlighted Gracell’s allogeneic CAR-T targeting CD7, Iovance’s TIL therapy in lung cancer, Gilead’s Yescarta/PD-L1 combination and the NCI’s bispecific CAR-T therapy.

t-lymphocyte. white blood cell. Lymphocyte. B-Lymphocyte. 3d illustration
Early lung cancer data were presented at AACR for Iovance's tumor-infiltrating lymphocytes • Source: Shutterstock

Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were presented during the American Association for Cancer Research virtual meeting with encouraging early activity, but these treatments also have hurdles to overcome.

Data from the first patients treated with novel cell therapy constructs and combinations from Gracell Biotechnologies Co. Ltd., Iovance Biotherapeutics Inc., Gilead Sciences Inc. and the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

More from Anticancer

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.